Identifying and Understanding Seizure Liability in Drug Development.

Area of Science:

• Neuroscience
• Pharmacology
• Drug Development

Background:

• Seizures are complex neurological events impacting brain function.
• Test article (TA)-induced seizures present significant challenges in pharmaceutical research and development.
• Understanding seizure manifestations and assessment is vital for drug safety evaluation.

Purpose of the Study:

• To outline methods for investigating test article-related seizure liabilities in nonclinical species.
• To emphasize the importance of distinguishing seizures from convulsions and understanding seizure types and phases.
• To guide the alignment of nonclinical seizure findings with clinical relevance for risk assessment.

Main Methods:

• Utilizing electroencephalography (EEG) for direct seizure confirmation in nonclinical studies.
• Employing functional observational batteries (FOB) and neurological examinations for clinical endpoint assessment.
• Analyzing neuropathological findings and biomarkers (CSF, serum) to identify seizure origin, frequency, and severity.

Main Results:

• EEG is the most direct method for confirming seizures in nonclinical safety testing.
• Clinical endpoints and neuropathological data provide crucial information on seizure liability.
• Accurate characterization of seizures is essential for determining clinical implications.

Conclusions:

• Regulatory bodies consider nonclinical seizure data and risk management strategies effective for clinical risk assessment.
• Distinguishing seizures from convulsions and understanding seizure nuances are key to evaluating clinical relevance.
• Comprehensive assessment integrating EEG, clinical endpoints, and neuropathology is vital for drug safety.